Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,442 across all filing types
Latest filing 2021-01-26 Capital/Financing Update
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Proposed issue of Securities - IMU 5 pages 28.1KB
Capital/Financing Update Classification · 95% confidence The document is titled 'Proposed issue of securities' and contains detailed information about a placement or other type of securities issue by Imugene Limited. It includes specifics such as the number of securities to be issued, issue price, approval requirements, and timetable. There is no indication of financial statements, earnings data, or management discussion. The content is focused on the announcement of a capital raising event or securities issuance. This matches the definition of a Capital/Financing Update (CAP). The document length is sufficient and contains substantive details about the securities issue, not just a brief notice or link to a report, so it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS). Therefore, the correct classification is CAP with high confidence.
2021-01-26 English
Appendix 2A 15 pages 394.9KB
Regulatory Filings Classification · 95% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX (Australian Securities Exchange). It includes detailed information about the entity, the securities to be quoted, and references to previous announcements such as Appendix 3B. This type of document is a regulatory announcement related to capital markets and securities issuance, specifically an application for quotation of new securities. It is not a financial report, earnings release, or management discussion. It is a formal regulatory filing to the exchange about securities quotation. Therefore, the most appropriate classification is 'Regulatory Filings' (RNS). The document length and content confirm it is not a brief announcement or a report publication announcement but a substantive regulatory form.
2021-01-26 English
Imugene Dose Escalates in PD1-VAXX Phase 1 Clinical Trial 2 pages 133.1KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Imugene Limited dated 21 January 2021. It announces the progression of a Phase I clinical trial dose escalation for their immunotherapy candidate PD1-Vaxx. The content focuses on clinical trial progress, safety review outcomes, and future trial steps. There are no financial statements, earnings data, or detailed financial analysis. The document is a corporate announcement about clinical trial progress rather than a financial report or regulatory filing. It is not a report publication announcement since it contains substantive information about the trial progress, not just a notice of report availability. The document fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about clinical trial progress and company development, which does not fit into other specific categories like earnings release or management report.
2021-01-20 English
IMUGENE COMPLETES RECRUITMENT TO HER-VAXX PHASE 2 TRIALIM 2 pages 105.7KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Imugene Limited reporting the completion of recruitment for a Phase 2 clinical trial of their HER-Vaxx immunotherapy for gastric cancer. It discusses clinical trial progress, patient enrollment, and study details. There are no financial statements, regulatory certifications, or detailed financial data. The content is an update on clinical trial progress and company activities rather than a financial report or regulatory filing. It is not a report publication announcement since it contains substantive information about the trial completion. The document fits best as a general regulatory announcement about company progress and clinical trial status, which aligns with the Regulatory Filings (RNS) category as a fallback for miscellaneous announcements that do not fit other categories.
2021-01-06 English
Change of Director's Interest Notice - PH 5 pages 324.3KB
Director's Dealing Classification · 100% confidence The document is an ASX announcement titled 'Appendix 3Y – Change of Director’s Interest Notice' for Executive Chairman Mr. Paul Hopper. It details changes in the director's relevant interests in securities, including shareholdings and options, and describes a funding arrangement involving shares as security. The document references ASX Listing Rule 3.19A.2 and the Corporations Act section 205G, which pertain to director's dealings disclosures. The content is focused on reporting a director's personal share transactions and related contractual interests. There is no financial performance data, earnings information, or management discussion. The document is not a report or announcement of a report but a regulatory disclosure of insider transactions. Therefore, it fits the category of Director's Dealing (DIRS). The document length (8136 characters) supports it being a full disclosure rather than a brief announcement or certification.
2020-12-22 English
Change of Director's Interest Notice - LC 3 pages 199.6KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including number of shares and options held before and after the change, nature of the change (exercise of options), and dates. This matches the definition of a Director's Dealing report, which reports personal share transactions by company directors and executives (insider trades). The document is not an announcement of a report, nor a full financial report, but a regulatory filing specifically about director share transactions. Therefore, the correct classification is DIRS.
2020-12-22 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.